definiens: shall mean the aggregate of : accumulated Clinical Trial Costs Contributions, plus the Initial Payment pursuantto Section 5.1, plus milestones paid pursuant to Section 5.3, all as actually paid byBIOGENETICS and received by ASLAN, plus sums actually paid byBIOGENETICS in relation to Regulatory Filings, all as shall have occurredbetween the Effective Date and the date of the Buy - Back Notice ; and ( b)a sum equal to two per cent ( 2 % ) of the upfront payment actually received byASLAN from the Global Deal ( ) . ASLAN undertakes toinform BIOGENETICS within thirty ( 30 ) days of receipt of such upfront paymentthat it has received the same, providing adequate details for the purposes of thisSection, and, upon receiving BIOGENETICS ’s correct invoice for the Share ofUpfront, to pay the Share of Upfront to BIOGENETICS within thirty ( 30 ) days ; and ( c)thereafter, two per cent ( 2 % ) of all royalties and sales milestones actuallyreceived by ASLAN from the Global Deal